EUVIMEDEUVIMED entdecken
Crossref

Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer Treatment

Ji-In Kim, Ye-Hyun Kim, Navin Pandit, Kyu Myung Lee, Chong Hak Chae, Doyoun Kim, Jae-Sung Kim, Kwan-Young Jung iD

Journal of Medicinal Chemistry · 09.04.2026 · 69 (7) · 8181-8214

DOI: 10.1021/acs.jmedchem.5c03599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.03.2026. Verfasst von Ji-In Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Protein Serine-Threonine Kinases, Quinazolines, Protein Kinase Inhibitors. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Korea Drug Development Fund, Korea Research Institute of Chemical Technology, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsProtein Serine-Threonine KinasesQuinazolinesProtein Kinase InhibitorsMicrotubule-Associated ProteinsHumansStructure-Activity RelationshipAnimalsFemaleCell Line, TumorCell ProliferationMiceApoptosis

Substanzen

Antineoplastic AgentsProtein Serine-Threonine KinasesQuinazolinesMASTL protein, humanProtein Kinase InhibitorsMicrotubule-Associated Proteins

Autor:innen und Institutionen

  • Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
  • College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
  • Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
  • Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon 34113, Republic of Korea.
  • Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea.
  • Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon 34113, Republic of Korea.

ORCID-Profile: Kwan-Young Jung

Förderung

  • Korea Drug Development Fund
  • Korea Research Institute of Chemical Technology
  • National Research Foundation of Korea
  • Korea Institute of Radiological and Medical Sciences

Zitieren

APA

Kim, J. I., Kim, Y. H., Pandit, N., Lee, K. M., Chae, C. H., Kim, D., Kim, J. S., & Jung, K. Y. (2026). Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer Treatment. Journal of Medicinal Chemistry, 69(7), 8181-8214. https://doi.org/10.1021/acs.jmedchem.5c03599

Vancouver

Kim JI, Kim YH, Pandit N, Lee KM, Chae CH, Kim D, et al. Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer Treatment. Journal of Medicinal Chemistry. 2026;69(7):8181-8214. doi:10.1021/acs.jmedchem.5c03599

BibTeX
@article{Kim2026,
  author = {Kim, Ji-In and Kim, Ye-Hyun and Pandit, Navin and Lee, Kyu Myung and Chae, Chong Hak and Kim, Doyoun and Kim, Jae-Sung and Jung, Kwan-Young},
  title = {Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {7},
  pages = {8181--8214},
  doi = {10.1021/acs.jmedchem.5c03599}
}
Kostenlos starten →